The global DNA manufacturing market size was estimated at USD 6.4 billion in 2025 and is anticipated to reach USD 23.1 billion by 2033, growing at a CAGR of 17.8% from 2026 to 2033. This growth is driven by increasing demand for gene therapies, personalized medicine, and advancements in synthetic biology.
Expanding applications in pharmaceutical research and vaccine development also contribute to market expansion. For instance, in July 2024, GenScript Biotech announced the launch of an advanced DNA synthesis platform that reduces production time, enabling faster development of gene therapies and synthetic vaccines.
For instance, in November 2024, NewBiologix launched its Xcell rAAV Production and Analytics Platform. It enables simultaneous screening of multiple rAAV candidates and provides comprehensive data reports that support preclinical and clinical development. Key features include detailed characterization of encapsulated DNA, including full and empty capsid ratios and gene sequence integrity, to accelerate gene therapy development. As more gene therapies progress through clinical trials and receive regulatory approvals, the demand for DNA manufacturing grows exponentially. The complexity and customization required for each treatment drive the need for advanced DNA synthesis technologies capable of producing high-quality DNA at scale and speed. Diseases like spinal muscular atrophy, certain types of inherited blindness, and blood disorders such as beta-thalassemia have experienced successful gene therapy treatments, fueling the market expansion of DNA manufacturing.
Improvements in sequencing technologies and bioinformatics have further streamlined quality control processes, ensuring that synthetic DNA products consistently meet the stringent standards required for clinical and research use. For instance, in March 2025, WuXi Biologics introduced the EffiX platform, an E. coli-based system designed to enhance recombinant proteins and plasmid DNA production, delivering high yield, stability, scalability, and cost-efficient manufacturing. This platform supports the efficient development and manufacturing of diverse biologics modalities. The continued adoption of automation and advanced technologies is transforming the market landscape by enabling rapid, high-quality production of complex DNA sequences at scale.
Expanding applications in pharmaceutical research and vaccine development also contribute to market expansion. For instance, in July 2024, GenScript Biotech announced the launch of an advanced DNA synthesis platform that reduces production time, enabling faster development of gene therapies and synthetic vaccines.
Growth of Gene Therapy
Gene therapies are transforming the treatment landscape for genetic disorders, rare diseases, and common chronic conditions. Gene therapies directly modify or replace faulty genes within a patient’s cells, offering the potential for long-lasting or curative effects. For instance, in September 2022, GenScript USA Inc. introduced the GenWand Double-Stranded DNA (dsDNA) service, designed to enhance CRISPR-based gene editing in T-cell engineering. This service offers covalently closed, linear DNA templates that are more stable and less prone to endonuclease degradation, thereby improving homology-directed repair (HDR) efficiency and reducing off-target effects compared to traditional PCR-based methods. This innovative approach requires large-scale production of highly precise, pure DNA sequences to develop therapeutic vectors, such as viral carriers or plasmids, that deliver corrective genes into patient cells.For instance, in November 2024, NewBiologix launched its Xcell rAAV Production and Analytics Platform. It enables simultaneous screening of multiple rAAV candidates and provides comprehensive data reports that support preclinical and clinical development. Key features include detailed characterization of encapsulated DNA, including full and empty capsid ratios and gene sequence integrity, to accelerate gene therapy development. As more gene therapies progress through clinical trials and receive regulatory approvals, the demand for DNA manufacturing grows exponentially. The complexity and customization required for each treatment drive the need for advanced DNA synthesis technologies capable of producing high-quality DNA at scale and speed. Diseases like spinal muscular atrophy, certain types of inherited blindness, and blood disorders such as beta-thalassemia have experienced successful gene therapy treatments, fueling the market expansion of DNA manufacturing.
Automation and Grade Improvements
Technological advancements and automation are revolutionizing the DNA manufacturing industry by improving accuracy and significantly reducing costs. Innovations such as silicon-based DNA synthesis, microfluidics, and AI-powered design tools enable high-throughput production with enhanced precision and reproducibility. For instance, in November 2023, Twist Bioscience launched Express Genes, a rapid gene synthesis service delivering NGS-verified clonal genes within five to seven days, leveraging its silicon-based platform and expanded manufacturing capacity.Improvements in sequencing technologies and bioinformatics have further streamlined quality control processes, ensuring that synthetic DNA products consistently meet the stringent standards required for clinical and research use. For instance, in March 2025, WuXi Biologics introduced the EffiX platform, an E. coli-based system designed to enhance recombinant proteins and plasmid DNA production, delivering high yield, stability, scalability, and cost-efficient manufacturing. This platform supports the efficient development and manufacturing of diverse biologics modalities. The continued adoption of automation and advanced technologies is transforming the market landscape by enabling rapid, high-quality production of complex DNA sequences at scale.
Global DNA Manufacturing Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, the analyst has segmented the global DNA manufacturing market based on type, grade, application, end use, and region:Type Outlook (Revenue, USD Million, 2021-2033)
- Plasmid DNA
- Synthetic DNA
- Gene Synthesis
- Oligonucleotide Synthesis
Grade Outlook (Revenue, USD Million, 2021-2033)
- GMP Grade
- R&D Grade
Application Outlook (Revenue, USD Million, 2021-2033)
- Cell & Gene Therapy
- Vaccines
- Oligonucleotide-based Drugs
- Others
End Use Outlook (Revenue, USD Million, 2021-2033)
- Pharmaceutical and Biotechnology Companies
- Academic & Research Institutes
- Contract Research Organizations
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. DNA Manufacturing Market: Type Business Analysis
Chapter 5. DNA Manufacturing Market: Grade Business Analysis
Chapter 6. DNA Manufacturing Market: Application Business Analysis
Chapter 7. DNA Manufacturing Market: End Use Business Analysis
Chapter 8. Regional DNA Manufacturing Market: Region Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Charles River Laboratories, Inc.
- VGXI, Inc.
- Danaher Corporation (Aldevron)
- Thermo Fisher Scientific
- Lonza
- GenScript
- Catalent
- Wuxi AppTec
- Kaneka Corp.
- Eurofins Genomics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | April 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 6.4 Billion |
| Forecasted Market Value ( USD | $ 23.1 Billion |
| Compound Annual Growth Rate | 17.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
